Salmonics’ cutting-edge technology stems from Sea Run Holdings Inc. (SRH), a pioneering biotech company founded in 1981 by Dr. Evelyn S. Sawyer. SRH revolutionized biomedical research by uncovering the powerful therapeutic potential of salmon plasma proteins for human and animal health.
One of SRH’s most groundbreaking discoveries was the unique hemostatic and proprietary pain-relieving properties of salmon fibrinogen and thrombin. With support from the NIH and U.S. Department of Defense, SRH conducted extensive preclinical trials, paving the way for a trauma bandage designed to stop severe bleeding. Their research also showed that salmon thrombin provided longer-lasting pain relief for fractures, burns, and surgeries than morphine.
Now, Salmonics is building on SRH’s legacy, advancing fish-derived therapeutics for the biomedical and pharmaceutical industries. By harnessing this untapped resource, Salmonics is driving innovations in wound healing, pain management, and beyond.
Dr. Cem Giray in the Salmonics lab